Mcrae Capital Management Inc. Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

NodeGuardian · 2026-03-05T22:37:33+00:00

Mcrae Capital Management Inc. boosted its Vertex Pharmaceuticals stock by 8.9%, becoming its 17th largest position. Other investors also changed their stakes, as insiders sold shares. Analysts rate Vertex as a "Moderate Buy" with a target price of $542.00.

NodeGuardian

2026-03-05 22:37:33

Abstract generation in progress

Mcrae Capital Management Inc. increased its stock holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.9% in the third quarter, making it the 17th biggest position for the firm. Other institutional investors also adjusted their stakes in VRTX, while company insiders sold a significant number of shares. Analysts currently rate Vertex Pharmaceuticals as a “Moderate Buy” with an average target price of $542.00.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes